Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative (ER PR Her2 Negative) Locally Advanced Non-Resectable and/or Metastatic Breast Cancer.

Trial Profile

Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative (ER PR Her2 Negative) Locally Advanced Non-Resectable and/or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Ixabepilone (Primary) ; Cetuximab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jul 2012 Merck KGaA and Merck Pharma SpA added as associations as reported in the European Clinical Trials Database record.
    • 26 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top